EURETINA Congress largest retina meeting

More than 6,800 gather in Paris for 19th EURETINA Congress

EURETINA Congress largest retina meeting
Colin Kerr
Colin Kerr
Published: Friday, September 6, 2019
[caption id="attachment_16349" align="alignleft" width="1024"] EURETINA President Sebastian Wolf addressing delegates at the Opening Ceremony of the 19th EURETINA Congress[/caption] Sebastian Wolf, president of EURETINA, told delegates attending the 19th EURETINA Congress in Paris that EURETINA today holds the title of largest retina meeting in the world. “The success of the annual Congress has been remarkable; EURETINA today holds the title of largest retina meeting in the world. And with more than 6,800 in attendance in Paris, including more than 5,600 delegates and more than 1,200 industry representatives, I am delighted to announce that this 19th Congress is also the largest in the history of the Society,” said Prof Wolf. Prof Wolf said the significance of EURETINA runs far beyond the success of its annual meetings. “This year we organised, with the help of the Czech Society, a successful educational Winter Meeting in Prague, while next March we look forward to bringing the Winter Meeting to Vilnius, Lithuania,” he said. Prof Wolf said education has always been high on the agenda for the society, both in its meeting and online endeavours. “This year the society took a major step by investing heavily in research and opening two funding calls in the field of research.” The introduction of the EURETINA Retinal Medicine Clinical Research Funding Call provides grant opportunities to EURETINA members of up to €300,000, said Prof Wolf (see page 4). Additionally, EURETINA teamed up with Fight for Sight to establish a call for funding of up to €2 million for clinical research projects, to address the best treatment option for sub-macular haemorrhage caused by AMD, a major unanswered question in retina. “Once again, an external team of expert judges was established to review applications, from which a clear winner was identified. The next challenge, given that this lead application is based in the UK, has been to navigate the potential complications of funding a clinical research trial in the context of Brexit. However, we are hopeful that we will manage and I am delighted to announce the winning applicant as Professor Timothy Jackson, of King’s College London (KCL).” Prof Wolf concluded his speech saying that the Congress was a culmination of the efforts of each chairperson, speaker and delegate, who has travelled to be here today. “On behalf of the Board I extend my sincere thanks to each of you and wish you an enjoyable congress and most pleasant stay here in Paris,” he said.
Tags: EURETINA
Latest Articles
Towards a Unified IOL Classification

The new IOL functional classification needs a strong and unified effort from surgeons, societies, and industry.

Read more...

Organising for Success

Professional and personal goals drive practice ownership and operational choices.

Read more...

Update on Astigmatism Analysis

Read more...

Is Frugal Innovation Possible in Ophthalmology?

Improving access through financially and environmentally sustainable innovation.

Read more...

iNovation Innovators Den Boosts Eye Care Pioneers

New ideas and industry, colleague, and funding contacts among the benefits.

Read more...

From Concept to Clinic

Partnerships with academia and industry promote innovation.

Read more...

José Güell: Trends in Cornea Treatment

Endothelial damage, cellular treatments, human tissue, and infections are key concerns on the horizon.

Read more...

Making IOLs a More Personal Choice

Surgeons may prefer some IOLs for their patients, but what about for themselves?

Read more...

Need to Know: Higher-Order Aberrations and Polynomials

This first instalment in a tutorial series will discuss more on the measurement and clinical implications of HOAs.

Read more...

Never Go In Blind

Novel ophthalmic block simulator promises higher rates of confidence and competence in trainees.

Read more...